COGT

Over the past six months, Cogent Biosciences experienced several stock-impacting events: the FDA accepted the NDA for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) on September 15, 2026, with a PDUFA date in June 2027, which reportedly caused a slight stock price decrease. The NDA for Bezuclastinib in AdvSM was submitted on June 30, 2026. The company reported its Second Quarter 2026 Financial Results on August 10, 2026. In May 2026, the NDA for Bezuclastinib in GIST was submitted under the FDA's Real-Time Oncology Review (RTOR) program. First Quarter 2026 Financial Results were reported on May 5, 2026. Upcoming potential FDA approval dates include November 30, 2026, for bezuclastinib in GIST and December 30, 2026, for Non-Advanced Systemic Mastocytosis (NonAdvSM). As of September 29, 2026, the stock price was $31.69, marking a 120.68% increase over the past year and a 91.5% gain over the past 12 months, though it saw a 9.3% decrease in the last month (September 9 to October 9, 2026). The stock's 52-week high was $43.73 and its low was $13.78.